PI3 kinase (p110β/p85α), FLAG-tag Recombinant
Complex of human PI3 kinase p110β, full-length, and human p85α, full length. The p110β construct contains an N-terminal FLAG-tag whereas p85α has no tag. The two recombinant proteins were co-expressed and affinity purified as a complex.
PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1 (Alpha), GRB1, p85alpha
≥85%
250 pmole/min/μg
PI3 (phosphoinositide 3) kinases, or phosphatidylinositol 3 kinases, are a family of proteins that can be subdivided into four classes: I, II, III and IV. Class I is involved in converting PI (4, 5) P2 (phosphatidylinositol (4, 5)-biphosphate) into PI (3, 4, 5) P3 (phosphatidylinositol (3, 4, 5)-triphosphate) when activated by tyrosine kinase receptors and G-protein coupled receptors. They are heterodimeric proteins with a regulatory and a catalytic subunit. The heterodimer between p110 (catalytic subunit) and p85 (regulatory subunit) belongs to class IA. p110 and p85 have three variants each. Class I PI3K participates in cell signaling, mostly via the activation of PKB (protein kinase B) and the PI3K/AKT/mTOR pathway. Dysfunction of these kinases impacts cell growth and differentiation, and mutations in p110α have been linked to cancer. At least three isoform-specific inhibitors are approved by FDA for the treatment of lymphoma and leukemia. Further studies will help identify more selective inhibitors with a good tolerance that can bypass the development of drug resistance.
2. Straub A. et al., (2008). Thromb. Haemost. 99 (3), 609-615.